Intrahepatic Cholangiocarcinoma

The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated unresectable or metastatic HER2-positive biliary tract cancer.

Several notable guideline updates have been made in gastroenterology and hepatology for the diagnosis, management and treatment of GI and liver disorders. Wondering what you may have missed?

CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.

Futibatinib demonstrated clinical benefit among previously treated patients with fibroblast growth factor receptor 2 fusion- or rearrangement-positive intrahepatic cholangiocarcinoma, according to results of a phase 2 study.

Atezolizumab plus cobimetinib significantly prolonged PFS compared with atezolizumab alone among a cohort of patients with advanced biliary tract cancer, according to results of a phase 2 study presented at the virtual American Association for Cancer Research Annual Meeting.

Primary liver cancer rates continue to increase in many regions of the world despite extensive efforts to prevent the disease, according to study results published in Cancer.

The FDA granted priority review to pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or rearrangements, according to a press release from the agent’s manufacturer.